Novartis announced new analyses of the data from PARADIGM-HF showing that Entresto (sacubitril/valsartan) consistently demonstrated benefit among heart failure patients with reduced ejection fraction (HFrEF), even when patients are considered clinically stable and regardless of background therapy.
An analysis of PARADIGM-HF patients found the following:
Even patients considered clinically stable - defined as patients with no history or a remote history of prior heart failure hospitalization - were still at risk for a serious clinical event.
In the analysis, over one third of patients were identified as clinically stable, and 20 per cent of those experienced a primary endpoint event (CV death or heart failure hospitalization). Among these patients, 51 per cent suffered CV death as their first event.
Further, the analysis determined that Entresto benefited patients considered clinically stable just as much as it did those who were least-stable (heart failure hospitalization within 3 months of baseline).
Among both groups, patients taking Entresto had a 20 per cent or greater reduction in CV death or heart failure hospitalization compared to those taking enalapril.
An analysis of PARADIGM-HF patients found the following:
Even patients considered clinically stable - defined as patients with no history or a remote history of prior heart failure hospitalization - were still at risk for a serious clinical event.
In the analysis, over one third of patients were identified as clinically stable, and 20 per cent of those experienced a primary endpoint event (CV death or heart failure hospitalization). Among these patients, 51 per cent suffered CV death as their first event.
Further, the analysis determined that Entresto benefited patients considered clinically stable just as much as it did those who were least-stable (heart failure hospitalization within 3 months of baseline).
Among both groups, patients taking Entresto had a 20 per cent or greater reduction in CV death or heart failure hospitalization compared to those taking enalapril.
No comments:
Post a Comment